ZNF784

Across TCGA pan-cancer cohorts, ZNF784 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF784 data layer compared with 19 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZNF784 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF784 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where ZNF784 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.712	0.955	.021	6	view →
LSCC	DFS	Median	All	1.000	0.899	.006	4	view →
LUAD	DFS	Median	All	0.860	0.998	.028	3	view →
GBM	DFS	Quartile	All	0.840	0.536	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZNF784–HNSC (OS)

Open the HNSC breakdown →